Skip to main content
SpringerLink
Log in
Book cover

Oncology of CNS Tumors pp 331–344Cite as

Primary CNS Lymphoma

  • Chapter

  • 1726 Accesses

Abstract

Primary CNS lymphoma (PCNSL) affects all age groups with a peak incidence in the fifth to seventh decades in non-AIDS patients. A slight male predominance is observed. The disease represents 2.6% of all primary brain tumors and 2–3% of NHLs [1, 53]. After a threefold rise observed between 1970 and 1990, the incidence of PCNSL has increased only slightly in the past 10 years in individuals above the age of 60, and now stands at 0.44/100,000 patient-years [1, 71]. With all forms of PCNSL, an occult systemic lymphoma is seldom found. Fewer than 10% of PCNSL patients present with brain and systemic lymphoma [85], and a similar percentage develop systemic disease after brain involvement.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. CBTRUS Supplement Report: Primary Brain Tumors in the United States, 2004. (2008) CBTRUS, Central Brain Tumor Registry of the United States, Hinsdale, IL

    Google Scholar 

  2. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043

    Article  PubMed  Google Scholar 

  3. Abrey LE, DeAngelis LM, Yahalom J. (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863

    PubMed  CAS  Google Scholar 

  4. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151–4156

    Article  PubMed  CAS  Google Scholar 

  5. Abrey LE, Yahalom J, DeAngelis LM. (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150

    PubMed  CAS  Google Scholar 

  6. Alderson L, Fetell MR, Sisti M, Hochberg F, Cohen M, Louis DN. (1996) Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 60:102–105

    Article  PubMed  CAS  Google Scholar 

  7. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al (2001) Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15:1483–1491

    Article  PubMed  CAS  Google Scholar 

  8. Baehring JM, Androudi S, Longtine JJ, Betensky RA, Sklar J, Foster CS, et al (2005) Analysis of clonal immuno-globulin heavy chain rearrangements in ocular lymphoma. Cancer 104:591–597

    Article  PubMed  CAS  Google Scholar 

  9. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. (2003) Neurolymphomatosis. Neuro Oncol 5:104–115

    PubMed  Google Scholar 

  10. Baehring JM, Hochberg FH, Betensky RA, Longtine J, Sklar J. (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247(2):208–216

    Article  PubMed  CAS  Google Scholar 

  11. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92:261–266

    Article  PubMed  CAS  Google Scholar 

  12. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 21:1044–1049

    Article  PubMed  CAS  Google Scholar 

  13. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715

    PubMed  CAS  Google Scholar 

  14. Bessell EM, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, et al (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231–236

    Article  PubMed  CAS  Google Scholar 

  15. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864–871

    PubMed  CAS  Google Scholar 

  16. Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J. (2006) Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 98:1088–1091

    Article  PubMed  Google Scholar 

  17. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, et al (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9:1063–1069

    PubMed  CAS  Google Scholar 

  18. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. (2004) Primary central nervous system posttrans-plant lymphoproliferative disorders. Am J Clin Pathol 121:246–253

    Article  PubMed  Google Scholar 

  19. Chamberlain MC, Kormanik PA. (1999) AIDS-related central nervous system lymphomas. J Neurooncol 43:269–276

    Article  PubMed  CAS  Google Scholar 

  20. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell JA, et al (2003) High-dose thiotepa, busulfan, cyclo-phosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31:679–685

    Article  PubMed  CAS  Google Scholar 

  21. Correa D, Maron L, Harder H, Klein M, Armstrong C, Calabrese P, et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145–1151

    Article  PubMed  CAS  Google Scholar 

  22. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555

    Article  PubMed  CAS  Google Scholar 

  23. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 20:4643–4648

    Article  PubMed  Google Scholar 

  24. DeAngelis LM, Yahalom J, Thaler HT, Kher U. (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635–643

    PubMed  CAS  Google Scholar 

  25. Drillenburg P, Pals ST. (2000) Cell adhesion receptors in lymphoma dissemination. Blood 95:1900–1910

    PubMed  CAS  Google Scholar 

  26. Ekenel M, Iwamoto FM, Ben Porat LS, Panageas KS, Yahalom J, DeAngelis LM, et al (2008) Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113:1025–1031

    Article  PubMed  CAS  Google Scholar 

  27. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903

    Article  PubMed  CAS  Google Scholar 

  28. Ferreri AJ, Blay J Y, Reni M, Pasini F, Gubkin A, Tirelli U, et al (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538

    Article  PubMed  CAS  Google Scholar 

  29. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272

    Article  PubMed  Google Scholar 

  30. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, et al (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353–358

    Article  PubMed  CAS  Google Scholar 

  31. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513–1520

    Article  PubMed  CAS  Google Scholar 

  32. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Roth A, et al (2008) Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 71:1102–1108

    Article  PubMed  CAS  Google Scholar 

  33. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141–1145

    Article  PubMed  CAS  Google Scholar 

  34. Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, et al (2003) Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563–568

    Article  PubMed  Google Scholar 

  35. Forsyth PA, DeAngelis LM. (1996) Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am 10:1125–1134

    Article  PubMed  CAS  Google Scholar 

  36. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70:401–402

    Article  PubMed  Google Scholar 

  37. Gijtenbeek JM, Rosenblum MK, DeAngelis LM. (2001) Primary central nervous system T-cell lymphoma. Neurology 57:716–718

    Article  PubMed  CAS  Google Scholar 

  38. Glass J, Hochberg FH, Miller DC. (1993) Intravascular lym-phomatosis. A systemic disease with neurologic manifestations. Cancer 71:3156–3164

    CAS  Google Scholar 

  39. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390–396

    Article  PubMed  CAS  Google Scholar 

  40. Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, et al (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18:1851–1855

    Article  PubMed  CAS  Google Scholar 

  41. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259–268

    Article  PubMed  CAS  Google Scholar 

  42. Harder H, Holtel H, Bromberg JE, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547

    Article  PubMed  CAS  Google Scholar 

  43. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849

    PubMed  CAS  Google Scholar 

  44. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, et al (2002) German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247–252

    Article  PubMed  CAS  Google Scholar 

  45. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, et al (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726–2731

    Article  PubMed  CAS  Google Scholar 

  46. Hochberg FH, Miller DC. (1988) Primary central nervous system lymphoma. J Neurosurg 68:835–853

    Article  PubMed  CAS  Google Scholar 

  47. Hochberg FH, Miller G, Schooley RT, Hirsch MS, Feorino P, Henle W. (1983) Central-nervous-system lymphoma related to Epstein-Barr virus. N Engl J Med 309:745–748

    Article  PubMed  CAS  Google Scholar 

  48. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al (2001) Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15:2119–2127

    Article  PubMed  CAS  Google Scholar 

  49. Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147–148

    Article  PubMed  CAS  Google Scholar 

  50. Iwamoto FM, Schwartz J, Pandit-Taskar N, Peak S, Divgi CR, Zelenetz AD, et al (2007) Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 110:2528–2534

    Article  PubMed  CAS  Google Scholar 

  51. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, et al (2006) Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24:4754–4757

    Article  PubMed  CAS  Google Scholar 

  52. Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, et al (2006) Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663–669

    Article  PubMed  Google Scholar 

  53. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  54. Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. (2002) Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58:175–178

    Article  PubMed  Google Scholar 

  55. Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, et al (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177

    Article  PubMed  Google Scholar 

  56. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62:451–456

    Article  PubMed  Google Scholar 

  57. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al (1998) The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histo-genetic derivation from germinal center-related B cells. Blood 92:1011–1019

    PubMed  CAS  Google Scholar 

  58. Linnebank M, Schmidt S, Kolsch H, Linnebank A, Heun R, Schmidt-Wolf IG, et al (2004) The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. Br J Cancer 90:1969–1971

    Article  PubMed  CAS  Google Scholar 

  59. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, et al (2008) First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (ZevalinTM) in primary CNS lymphoma. Neuro Oncol [Epub ahead of print]

    Google Scholar 

  60. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–60

    Article  PubMed  CAS  Google Scholar 

  61. McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH. (2008) Primary CNS lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood 71(14):1102–1108

    Google Scholar 

  62. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al (2000) AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 356:291–296

    Article  PubMed  CAS  Google Scholar 

  63. Montesinos-Rongen M, Kuppers R, Schluter D, Spieker T, Van Roost D, Schaller C, et al (1999) Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4–34 gene segment. Am J Pathol 155:2077–2086

    Article  PubMed  CAS  Google Scholar 

  64. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. (2004) Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103:1869–1875

    Article  PubMed  CAS  Google Scholar 

  65. Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, et al (2003) Novel tumor suppressor loci on 6q22–23 in primary central nervous system lymphomas. Cancer Res 63:737–741

    PubMed  CAS  Google Scholar 

  66. Nelson DF. (1999) Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 43:241–247

    Article  PubMed  CAS  Google Scholar 

  67. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17

    Article  PubMed  CAS  Google Scholar 

  68. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526

    PubMed  Google Scholar 

  69. O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. (1999) Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med Oncol 16:211–215

    Article  PubMed  Google Scholar 

  70. Ohguro N, Hashida N, Tano Y. (2008) Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 126:1002–1003

    Article  PubMed  CAS  Google Scholar 

  71. Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95:1504–1510

    Article  PubMed  Google Scholar 

  72. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, et al (2009) Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 91:299–305

    Article  PubMed  CAS  Google Scholar 

  73. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21(24):4489–4495

    Article  PubMed  CAS  Google Scholar 

  74. Pels H, Schulz H, Schlegel U, Engert A. (2003) Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26:351–354

    Article  PubMed  CAS  Google Scholar 

  75. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose metho-trexate. Clin Cancer Res 10:5643–5646

    Article  PubMed  CAS  Google Scholar 

  76. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al (2008) Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 22:301–306

    Article  PubMed  Google Scholar 

  77. Poortmans P, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-aids-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21(24):4483–4488

    Article  PubMed  CAS  Google Scholar 

  78. Reni M, Ferreri AJ. (2001) Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80 (3):B113–B117

    PubMed  CAS  Google Scholar 

  79. Reni M, Ferreri AJ, Guha-Thakurta N, Blay J Y, Dell'Oro S, Biron P, et al (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51:419–425

    Article  PubMed  CAS  Google Scholar 

  80. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, et al (2003) Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965–971

    PubMed  CAS  Google Scholar 

  81. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350–1356

    Article  PubMed  CAS  Google Scholar 

  82. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723

    Article  PubMed  CAS  Google Scholar 

  83. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990– 1998. Neurology 56:257–260

    Article  PubMed  CAS  Google Scholar 

  84. Schlegel U, Schmidt-Wolf IG, Deckert M. (2000) Primary CNS lymphoma: clinical presentation, pathological classifi-cation, molecular pathogenesis and treatment. J Neurol Sci 181:1–12

    Article  PubMed  CAS  Google Scholar 

  85. Schlegel U, Schmidt-Wolf IG, Deckert M. (2000) Primary CNS lymphoma: clinical presentation, pathological classifi-cation, molecular pathogenesis and treatment. J Neurol Sci 181:1–12

    Article  PubMed  CAS  Google Scholar 

  86. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexame-thasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol 14:556–564

    PubMed  CAS  Google Scholar 

  87. Schwindt H, Akasaka T, Zuhlke-Jenisch R, Hans V, Schaller C, Klapper W, et al (2006) Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 65:776–782

    Article  PubMed  CAS  Google Scholar 

  88. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730–4735

    Article  PubMed  CAS  Google Scholar 

  89. Shenkier TN, Blay J Y, O'Neill BP, Poortmans P, Thiel E, Jahnke K, et al (2005) Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 23:2233–2239

    Article  PubMed  Google Scholar 

  90. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101:815–821

    Article  PubMed  CAS  Google Scholar 

  91. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716

    Article  PubMed  Google Scholar 

  92. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512–2518

    Article  PubMed  Google Scholar 

  93. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749

    PubMed  CAS  Google Scholar 

  94. Springer TA. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314

    Article  PubMed  CAS  Google Scholar 

  95. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. (1999) V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94:1738–1746

    PubMed  CAS  Google Scholar 

  96. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86:211–215

    Article  PubMed  CAS  Google Scholar 

  97. Weber T, Weber RG, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, et al (2000) Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 10:73–84

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Yale University School of Medicine, 333 Cedar Street, TMP 412, New Haven, CT, 06510, USA

    Joachim M. Baehring

  2. Knappschaftskrankenhaus, Klinik für Neurologie, In der Schornau 23-25, Bochum, 44892, Germany

    Uwe Schlegel

  3. Massachusetts General Hospital, Brain Tumor/Oncology Center, Yawkey 9010, Boston, MA, 02114, USA

    Fred H. Hochberg

Authors
  1. Joachim M. Baehring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Schlegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fred H. Hochberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim M. Baehring .

Editor information

Editors and Affiliations

  1. Universitätsklinikum München Klinikum Großhadern Neurochirurgische Klinik, Marchioninistr. 15, München, 81377, Germany

    Jörg-Christian Tonn

  2. Universitätsklinikum Hamburg Krankenhaus Eppendorf Klinik und Poliklinik für Neurochirurgie, Martinistr. 52, Neurologie, Hamburg, 20246, Germany

    Manfred Westphal

  3. Division of Neurosurgery, The Hospital for Sick Children, 555 University Avenue Suite 1502, Toronto, ON, M5G 1X8, Canada

    James T. Rutka

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Baehring, J.M., Schlegel, U., Hochberg, F.H. (2010). Primary CNS Lymphoma. In: Tonn, JC., Westphal, M., Rutka, J.T. (eds) Oncology of CNS Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02874-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-02874-8_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-02873-1

  • Online ISBN: 978-3-642-02874-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation